Although only recently adopted in RP, Anakinra is approved by United States Food and Drug Administration (FDA) for the treatment of Rheumatoid Arthritis (RA), cryopyrin-associated periodic syndromes (CAPS), TRAPS, and FMF [18]. This evidence concerns the gene NLRP3 and rheumatoid arthritis.